Thryv Therapeutics to Present at UBS Global Biopharma Conference in London, Showcasing New Innovations

Thryv Therapeutics at the UBS Global Biopharma Conference

Thryv Therapeutics Inc., a prominent clinical-stage biotechnology firm, is set to participate in the upcoming UBS Global Biopharma Conference scheduled for November 16-17, 2026, in the vibrant city of London. This event is widely recognized as a key platform for showcasing advancements in the biopharmaceutical sector.

Leadership Presentation
At the conference, Thryv’s Chairman and CEO, Paul Truex, will present on November 17 at 320 PM GMT (1020 AM ET). His presentation promises to provide investors and stakeholders with crucial insights into the company’s ongoing projects and future directions. This will include a discussion on their innovative therapies aimed at inherited channelopathies, cardiometabolic diseases, and cardiomyopathies, emphasizing their precision medicine approach.

Pausing to Appreciate Progress
One highlight of the presentation will be the recent closing of a significant $30 million Series B financing round, co-led by InClin, Inc. This funding will bolster their clinical programs, enabling them to continue pushing the envelope in biopharmaceutical innovation.

Pipeline Development
Thryv Therapeutics is particularly excited to share updates on their lead candidate, THRV-1268. This selective inhibitor targets serum glucocorticoid-inducible kinase 1 (SGK1), a crucial player in various heart diseases. The company has successfully completed enrollment in the first efficacy cohort of Wave II, a Phase 2/3 study examining THRV-1268’s efficacy in patients with Long QT Syndrome (NCT07277582). They anticipate emerging data early in 2027, which could potentially set new standards in treatment for this condition.

Moreover, the establishment of clinical operations in Australia marks another milestone for Thryv, preparing for the enrollment phase to commence in early 2027 for the ASPIRE-HF study. This Phase 2a trial will focus on patients suffering from heart failure with reduced ejection fraction (HFrEF) and QTc prolongation, further illustrating the broad application of their therapies.

The Broader Significance
Thryv Therapeutics stands at a pivotal intersection where electrical and structural heart diseases converge. The SGK1 mechanism offers a unique opportunity to combat the inflammation and fibrosis driving adverse remodeling of the heart. Their ongoing clinical trials—including the one for THRV-1268—could provide vital data to advance understanding and treatment of these complex conditions.

As the conference approaches, Thryv Therapeutics invites interested parties to request one-on-one meetings to discuss their developments and future contributions to the biopharma sector. More detailed information can be accessed through their official website at www.thryvtrx.com.

Overall, Thryv Therapeutics is significantly advancing the field of precision medicine with their innovative approach to heart disease treatment. The company’s participation in the UBS Global Biopharma Conference symbolizes their commitment to fostering dialogue around groundbreaking research and enhancing healthcare outcomes.